主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
AVBP
#2111
ArriVent BioPharma, Inc. Common Stock
22.9
7
+0.22%
版块:
基础:
利润货币:
日范围
年范围
日变化
+0.22%
每月变动
-1.20%
6个月变化
+19.57%
年变化
-4.01%
前一天收盘价
22.9
2
Open
22.9
3
Bid
Ask
Low
22.9
3
High
22.9
7
交易量
76
市场
股票
医疗保健
AVBP
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2024
Total assets
274.94 M
Total liabilities
17.29 M
Total equity
257.65 M
Total liabilities & shareholders' equities
274.94 M
Total debt
—
Net debt
—
新闻
Cantor Fitzgerald重申ArriVent股票评级为"增持"
ArriVent stock rating reiterated as Overweight by Cantor Fitzgerald
Oppenheimer维持ArriVent BioPharma股票"跑赢大盘"评级
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock
ArriVent BioPharma (AVBP): Its Leading Asset, Furmonertinib, Supports A Cautious Buy
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP)
Cantor Fitzgerald 给予ArriVent BioPharma股票"增持"评级
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug
BTIG给ArriVent BioPharma股票首次评级为"买入",看好其肿瘤治疗潜力
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential
Truist证券给予ArriVent BioPharma买入评级,看好其肺癌药物前景